Grey Wolf Therapeutics Ltd. added $50 million to its series B, bringing the total for the round to $99 million and providing funding to expand the scope of an ongoing phase I/II trial of its lead antigen modulation program.

Biopharmas raising money in public or private financings, including: Bicycle, Cytokinetics, Foghorn, Radar, Rakovina.

Med-tech firms raising money in public or private financings, including: Allez, Haemonetics.

Biopharmas raising money in public or private financings, including: Biodexa, Captain T Cell, Dyne, Erasca, Imvax, Neophore, Sixpeaks.

Med-tech firms raising money in public or private financings, including: Haemonetics.

Sixpeaks Bio AG has emerged from stealth with $30 million in series A financing and a pipeline of therapies for healthy weight loss, including a dual-specific antibody targeting activin type IIA and B receptors for preservation of skeletal muscle mass.

Altrubio Inc. secured up to $225 million in an oversubscribed series B financing round, led by BVF Partners LP. The full amount is dependent on Altrubio meeting certain undisclosed milestones. New investors RA Capital Management, Cormorant Asset Management and Soleus Capital, and existing investors Amoon Fund and Blackstone Multi-Asset Investing, as well as other new and existing investors, also participated in the financing round.

Biopharmas raising money in public or private financings, including: Dyne, GT, Mymd, Progentos, Ygion.